SG Americas Securities LLC Has $75,000 Stake in Lyell Immunopharma, Inc. (NASDAQ:LYEL)

SG Americas Securities LLC increased its position in Lyell Immunopharma, Inc. (NASDAQ:LYEL) by 102.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 116,748 shares of the company’s stock after purchasing an additional 59,182 shares during the period. SG Americas Securities LLC’s holdings in Lyell Immunopharma were worth $75,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. China Universal Asset Management Co. Ltd. lifted its stake in Lyell Immunopharma by 64.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 49,238 shares of the company’s stock valued at $68,000 after acquiring an additional 19,287 shares in the last quarter. Centiva Capital LP purchased a new stake in Lyell Immunopharma in the 3rd quarter worth about $31,000. Exchange Traded Concepts LLC increased its holdings in Lyell Immunopharma by 37.3% in the 3rd quarter. Exchange Traded Concepts LLC now owns 135,050 shares of the company’s stock worth $186,000 after acquiring an additional 36,715 shares during the last quarter. Intech Investment Management LLC purchased a new position in Lyell Immunopharma during the 3rd quarter valued at about $52,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in Lyell Immunopharma during the 3rd quarter valued at about $52,000. 66.05% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on LYEL. HC Wainwright reissued a “neutral” rating and set a $1.00 price objective on shares of Lyell Immunopharma in a report on Tuesday, November 12th. Bank of America downgraded Lyell Immunopharma from a “buy” rating to an “underperform” rating and lowered their price objective for the company from $6.00 to $1.00 in a research report on Wednesday, October 30th.

Lyell Immunopharma Stock Up 8.4 %

Shares of LYEL stock opened at $0.58 on Friday. The stock has a market cap of $170.04 million, a price-to-earnings ratio of -0.74 and a beta of -0.35. The business’s fifty day moving average is $0.64 and its 200 day moving average is $1.03. Lyell Immunopharma, Inc. has a twelve month low of $0.51 and a twelve month high of $3.26.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.